Respiratory System Changes in Different Environments

Physiology, Adaptation, and Clinical Implications

Marib Ghulam Rasool Malik

Naveed ur Rehman Siddiqui

Objectives

Introduction

Physiological effects of reduced barometric pressure and inspired oxygen

Oxyhemoglobin dissociation curve - Clinical implications for oxygen loading and unloading

Altitude influences ventilation-perfusion matching, gas exchange, and heart-lung interactions

Unique risks altitude poses in patients with heart failure, COPD, ILD, and pulmonary hypertension Diagnosis

Pre-travel assessment strategies and preventive measures for individuals with cardiopulmonary disease

Available respiratory support interventions at altitude

Recommendations for patient counseling, safe travel

management of altitude-related hypoxemia

Conclusion

References

Introduction

Human physiology is significantly influenced by environmental conditions, and most noticeably by conditions of atmospheric pressure and oxygen availability. High altitude provides a hypobaric, low-pressure, and lower-oxygen environment that strains the cardiopulmonary system. Although millions of people each year visit or reside at high altitudes worldwide, altitude physiology remains of academic as well as clinical importance. Those with lung or heart diseases are most vulnerable at high altitude.

Under normal sea level conditions, the cardiopulmonary system operates at normal barometric pressure, but at high altitude, there is diminished ambient pressure and partial pressure of inspired gases (PiG). The compensatory mechanisms of the body are engaged to provide delivery of oxygen (for example, hyperventilation and high heart rates) but may be suboptimal at higher altitudes. This chapter provides a comprehensive overview of respiratory physiology and heart–lung interactions across altitudes, linking foundational principles with current literature and clinical scenarios. We discuss how respiratory and hemodynamic parameters and autonomic control vary over sea level to higher altitudes and how this applies to disease conditions like heart failure, chronic lung disease, and others.

High-altitude physiology is more than "thin air" – it is the thin line between ventilation, circulation, and oxygen delivery. A comparison of extreme environments and ordinary sea levels allows us to better grasp how stressors like hypoxia and cold provide windows into physiological thresholds. This insight, in turn, educates us on how to counsel patients and how to manage altitude illness. We begin with key concepts of gas exchange and cardiopulmonary physiology and then consider environmental settings, heart-lung interactions at altitude, clinical applications, supporting strategies, and practical uses. Altitude affects all of us, though not equally, and an understanding of why this will enable us to care better for both healthy individuals and those with cardiopulmonary disease.

Foundations of Respiratory Physiology

Gas Laws and Atmospheric Pressure Variations

The availability of oxygen in the air is determined by barometric pressure and the fraction of oxygen (21% at all altitudes for ambient air). Dalton's law states that the partial pressure of a gas is the product of the total pressure and the gas's concentration. At sea level (760 mmHg), the partial pressure of inspired oxygen (PiO_2) is about 160 mmHg (21% of 760 mmHg), whereas at high altitude, the barometric pressure falls and thus PiO_2 drops proportionally. For instance, at ~2360 m, atmospheric pressure is only ~75% of sea-level pressure; at ~5050 m, it's ~53%. This means the inspired oxygen pressure at 5050 m is roughly half that at sea level. Lower PiO_2 leads to lower alveolar oxygen partial pressure (PAO_2) and arterial oxygen partial pressure (PaO_2) unless physiologic adjustments occur. According to the alveolar gas equation, alveolar O_2 tension depends on PiO_2 minus the "dilution" by water vapor and CO_2. At sea level, with normal ventilation, alveolar O_2 ~100 mmHg; at 3500 m, alveolar O_2 falls to ~55– 60 mmHg even with hyperventilation. Table 1 compares key cardiopulmonary values at sea level and high altitude. Notably, the reduced barometric pressure at altitude is the primary driver of hypoxemia; other factors like latitude, temperature, and humidity have comparatively minor effects.

The hallmark of high altitude is hypoxemia with arterial O_2 ~60 mmHg and O_2 saturation around 88–90% in otherwise healthy individuals. The body responds by increasing ventilation and heart rate to maintain oxygen delivery. Arterial CO_2 falls (respiratory alkalosis), and over days, the kidney compensates by excreting bicarbonate. Pulmonary artery pressure rises because low alveolar O_2 triggers hypoxic pulmonary vasoconstriction (HPV). Over longer times, hematocrit increases to augment O_2 carrying capacity. These fundamental changes underline many clinical manifestations of altitude exposure.

Table 1. Key Cardiopulmonary Parameters at Sea Level and High Altitude

Parameter	Sea Level (~0 m)	High Altitude (~3,500 m)
Barometric pressure (Pb)	~760 mmHg	~495–520 mmHg
Inspired O_2 partial pressure (PiO_2)	~160 mmHg	~110-104 mmHg
Alveolar O_2 (PAO_2)	~100 mmHg	~55–60 mmHg (with hyperventilation)
Arterial O_2 (PaO_2)	~95–100 mmHg	~55–65 mmHg
O_2 saturation (SaO_2)	~97–99%	~88–92%
Arterial CO_2 ($PaCO_2$)	~40 mmHg	~30 mmHg (respiratory alkalosis)
pH	~7.40	7.45–7.50 (acute alkalosis, later compensated by renal HCO_3^- excretion)
Cardiac output	Normal (5 L/min at rest)	↑
Heart rate	60–80 bpm	↑ 20–30% above baseline
Pulmonary artery pressure (PAP)	15–20 mmHg mean	25–30 mmHg mean
Hematocrit	~42–45%	↑ after days (46–50%)

Oxygen Transport and the Oxyhemoglobin Dissociation Curve

Oxygen in blood is carried predominantly by hemoglobin (Hb), and the oxyhemoglobin dissociation curve describes the saturation of Hb (SaO_2) at varying O_2 tensions. This S-shaped curve is steep at lower PO_2 and plateaus at higher PO_2. At sea level, arterial PO_2 ~95 mmHg yields SaO_2 ~97–99%. At a PO_2 of 55-60 mmHg (which might occur at higher altitude), SaO_2 drops to around 89–90% – illustrating the steep portion of the curve. Several factors shift the curve (Figure 1).

At high altitude, the oxyhemoglobin curve is influenced by two competing effects: (1) Increased 2,3-diphosphoglycerate (2,3-DPG) in red blood cells, which occurs within hours to days of hypoxia, binds hemoglobin and reduces O_2 affinity (right shift). This facilitates the unloading of O_2 to tissues. (2) Respiratory alkalosis from hyperventilation, which (after partial renal compensation) tends to increase Hb-O_2 affinity (left shift). In moderate altitudes (e.g., 2500–4500 m), the 2,3-DPG effect usually predominates, yielding a slight rightward shift of the curve. However, at extreme altitudes (>5400 m), hyperventilation is so pronounced that a significant alkalosis persists, shifting the curve back leftward. In fact, humans at ~7000–8000 m show an increase in Hb-O_2 affinity as an adaptive strategy to load oxygen in severely hypoxic alveoli. Thus, acclimatization involves a delicate balance: initially, a right shift for tissue oxygenation, but at the limits of altitude, preserving arterial O_2 content by a left shift. Clinically, this means that at moderate to high altitude, a given drop in PO_2 causes less desaturation than it would at sea level (due to 2,3-DPG). However, at extreme altitude, the blood holds O_2 more tightly, which may impair tissue delivery despite decent saturation. Importantly, hypoxemia in patients (e.g., with lung disease) can also shift the curve; for instance, chronic hypoxemia raises 2,3-DPG levels, aiding O_2 release. In contrast, if a patient with chronic CO_2 retention is given excess oxygen (reducing ventilation drive and causing CO_2 rise and acidosis), the curve may shift right and further impede loading in the lungs. Therefore, understanding the O_2–Hb curve helps predict how altitude or disease will affect oxygenation.



Figure 1: The oxyhemoglobin dissociation curve illustrating shifts in oxygen affinity at varying altitudes and changes in other factors. [Adapted from reference 2)

Ventilation–Perfusion (V/Q) Matching

Efficient gas exchange requires matching of ventilation (airflow to alveoli) and perfusion (blood flow to pulmonary capillaries). At sea level in an upright person, there is a normal gradient of V/Q ratios in the lung: apices have higher V/Q (more ventilation relative to perfusion) and bases have lower V/Q (more perfusion). Small degrees of V/Q mismatch and anatomic shunt (for example, bronchial circulation, thebesian veins) explain the slight difference between alveolar and arterial O_2 (A–a gradient ~5–10 mmHg in healthy people). The lung compensates for localized low ventilation by hypoxic pulmonary vasoconstriction – for instance, if one alveolus is under ventilated, the arterioles feeding it constrict to divert blood to better ventilated units. This mechanism optimizes V/Q matching at baseline. At high altitude, however, global alveolar hypoxia occurs, all alveoli have lower PAO_2. The pulmonary vasculature responds with diffuse hypoxic vasoconstriction. Instead of improving V/Q match, this now elevates pulmonary artery pressure and can worsen gas exchange, resulting in dead space ventilation. The reason is that high pulmonary vascular resistance can lead to uneven perfusion (some capillaries may constrict more than others) and microvascular stress failures. Indeed, two factors thought to widen the A-a gradient at altitude are subtle pulmonary edema (fluid in alveoli) and reopening of small shunts. In other words, high altitude itself causes a mild V/Q mismatch even in healthy lungs, due to uneven blood flow and slight pulmonary edema that develops especially with exertion or in susceptible individuals. The classic example is high-altitude pulmonary edema (HAPE), where patchy edema in the lungs leads to severe V/Q mismatch, shunt, and hypoxemia (often disproportionate to the altitude). Even without frank HAPE, studies show that at altitude the A–a gradient increases, meaning arterial O_2 is lower than expected from PAO_2, owing to less than perfect V/Q matching and diffusion limitation. Ventilation–perfusion physiology also explains why giving supplemental oxygen can be so beneficial: raising PAO_2 can overcome moderate V/Q mismatch and significantly improve arterial saturation (because even poorly ventilated units get some extra O_2). In summary, V/Q matching is a cornerstone of gas exchange; altitude challenges it by inducing global hypoxic pulmonary vasoconstriction (HPV) and predisposing to small shunts, whereas lung diseases (COPD, fibrosis, etc.) create their own V/Q disturbances that altitude can exacerbate.

Basics of Heart–Lung Interactions

The heart and lungs are anatomically intertwined in the thorax, and changes in intrathoracic pressure with breathing can influence cardiac function. Under normal conditions at sea level (eupnea), these interactions are subtle but measurable. During spontaneous inspiration, the diaphragm descends and intrathoracic pressure becomes more negative. This negative pressure boosts venous return to the right heart, increasing right ventricular (RV) preload and stroke volume. At the same time, the increased lung volume slightly stretches pulmonary capillaries. It raises pulmonary vascular resistance, and the expanded RV can push the interventricular septum toward the left; both factors can transiently reduce left ventricular (LV) filling in severe cases of persistent pulmonary hypertension with RV dilatation. Additionally, the more negative intrathoracic pressure increases LV afterload by raising transmural pressure (the LV must pump against a higher difference between inside and outside pressure). As a result, LV stroke volume may fall a bit during inspiration, which is one reason systolic blood pressure can drop slightly with a deep breath (physiological pulsus paradoxus, normally <10 mmHg drop). During expiration, the opposite happens: intrathoracic pressure becomes less negative (or briefly positive if one forcefully exhales), reducing venous return (lower RV preload), but easing LV afterload and allowing the LV to fill a bit better. These see-saw effects are usually mild in healthy people. However, in conditions like cardiac tamponade or severe asthma, the exaggerated swings in intrathoracic pressure cause a pronounced pulsus paradoxus.

Mechanical ventilation inverts these dynamics. With positive-pressure ventilation (as in intubated patients or someone on CPAP/BiPAP), each insufflation raises intrathoracic pressure. This can impede venous return and reduce RV preload. High lung volumes compress pulmonary vessels, increasing RV afterload. Meanwhile, the positive pressure decreases LV afterload (since the pressure around the LV is higher, reducing transmural stress) and can actually augment LV output if the LV was failing. Positive end-expiratory pressure (PEEP) further elevates baseline intrathoracic pressure, which may improve oxygenation (by preventing alveolar collapse) at the expense of cardiac output (by constantly impeding venous return). These heart–lung interactions are important in critical care and also play a role in exercise and disease states at altitude. For example, at high altitude, people tend to hyperventilate; the larger swings in intrathoracic pressure might accentuate these interactions slightly. In COPD with dynamic hyperinflation (air-trapping), intrinsic PEEP develops even during spontaneous breathing, elevating intrathoracic pressure and straining the RV. In heart failure, using noninvasive positive-pressure ventilation (like CPAP) can offload the failing LV by reducing afterload. Thus, a solid grasp of heart–lung mechanics is essential for understanding how interventions (oxygen, ventilation support) at altitude will affect patients.

Environmental Contexts and Their Physiological Impacts

Altitude and climate extremes vary widely, from the oxygen rich air at sea level to the thin, frigid atmosphere at the top of Everest. Here, we consider several contexts and how they impact respiratory physiology.

Sea Level (Baseline)

At sea level, barometric pressure is ~760 mmHg, and inspired oxygen (21%) yields a PiO_2 of ~160 mmHg (reducing to ~100 mmHg in alveoli after humidification and CO_2 exchange). The human body is well-adapted to this environment, arterial O_2 ~95–100 mmHg, SaO_2 ~98%, and tissue oxygenation is easily met under resting conditions. Ventilation is primarily driven by CO_2 (via central chemoreceptors) with a secondary hypoxic drive (quiescent at normal O_2 levels). Pulmonary artery pressures are low, and HPV is inactive except in poorly ventilated lung units. In essence, sea level provides a generous supply of O_2, and the cardiopulmonary system operates with a comfortable reserve. For example, a healthy person at rest has an oxygen saturation near 98% and a mixed venous O_2 saturation of ~75% indicating that even at rest, only about 25% of carried O_2 is extracted by tissues. This reserve can be mobilized during exercise. The normal A–a gradient is small (~5–10 mmHg), meaning efficient gas exchange. Understanding this baseline is important because it is the reference against which altitude changes are measured.

From a clinical perspective, “sea level” conditions can be achieved therapeutically by increasing FiO_2 or using hyperbaric oxygen in certain scenarios. Conversely, even mild deviations from sea level pressure cause noticeable physiological changes. But at baseline, our physiology is tuned to ~1 atm pressure, 21% O_2, and moderate climates.

High Altitude (> 2500 m)

High altitude is typically defined as elevations >1500–2500 m (5,000–8,000 ft), with 3500–5500 m termed very high, and >5500 m extreme altitude. In high mountainous environments, the drop in barometric pressure leads to hypobaric hypoxia, the central feature of altitude physiology. At 3000 m (a typical ski resort altitude), barometric pressure is only about 526 mmHg, and PiO_2 ~110 mmHg. Alveolar O_2 might be ~60 mmHg after hyperventilation, resulting in arterial O_2 saturations in the low 90s for healthy newcomers. The immediate response is activation of peripheral chemoreceptors (carotid bodies) due to low arterial O_2. Within minutes of ascent, ventilation increases

(hyperventilation), which raises alveolar O_2 somewhat but also causes CO_2 to drop. The symptoms many feel on rapid ascent – shortness of breath, lightheadedness, tingling (from alkalosis) – reflect this ventilatory response. Cardiac output initially increases (mostly via heart rate) to boost O_2 delivery. Sympathetic nervous activity surges, elevating heart rate and blood pressure. Even at rest, someone at 3500 m may have a heart rate 20% higher than at sea level and a modest increase in blood pressure due to catecholamine release.

Crucially, hypoxic pulmonary vasoconstriction kicks in uniformly in both lungs, raising pulmonary artery pressure. Acutely, this can double from sea-level values, especially in individuals with strong HPV responses. This elevated pulmonary artery pressure increases the workload on the RV. Most people tolerate moderate pulmonary artery pressure increases, but those with borderline cardiopulmonary reserve might develop problems (such as pulmonary edema or RV strain). As discussed, V/Q matching is altered: HPV helps reduce shunting from poorly ventilated regions, but at altitude, essentially all regions are "poorly ventilated" (relative to sea level), so HPV causes a global increase in pulmonary resistance.

Over ensuing hours to days, acclimatization occurs. The kidneys compensate for respiratory alkalosis by excreting bicarbonate, allowing ventilation to remain elevated without causing a severe pH change. This renal diuresis often leads to noticeable fluid loss (altitude diuresis), mountain climbers frequently experience increased urine output and dehydration if they do not maintain intake. The hemoconcentration from diuresis actually raises blood O_2 content slightly (higher hematocrit). Over 1–2 weeks, erythropoietin from the kidneys increases RBC production, further boosting hemoglobin levels. Acclimatized individuals at 3000–4000 m may have hemoglobin concentrations 2–3 g/dL above baseline, partially compensating for lower O_2 saturation. Ventilation continues to rise over a period of days ("ventilatory acclimatization"), which improves arterial O_2 (often SaO_2 creeps up a few percentage points after a week at altitude as one breathes deeper/faster). However, even with full acclimatization, oxygen availability remains significantly lower than at sea level. Physical performance is curtailed (VO_2max declines with altitude), and even daily activities can cause breathlessness until one adapts. Common altitude illnesses can occur: acute mountain sickness (AMS) (headache, nausea, fatigue) in unacclimatized travelers typically above 2500 m, High-Altitude Cerebral Edema (HACE) (rare, extreme AMS progression with ataxia, confusion), and High-Altitude Pulmonary Edema (HAPE) (potentially fatal, due to maladaptive high PAP and uneven HPV causing fluid leak).

Extremely High Altitudes (Above ~5500 m)

"Extreme" altitude is typically > 5500 m (18,000 ft). The summit of Mount Everest (8848 m) represents an almost unsurvivable environment without supplemental oxygen, the barometric pressure there is only ~250 mmHg, and PiO_2 ~52 mmHg (one-third of sea level). Even with maximal hyperventilation, alveolar O_2 on Everest's summit may be only ~30 mmHg, and arterial O_2 saturations in climbers can dip into the 50–70% range during rest and exercise. This is near the limit of human tolerance; above ~7500 m ("death zone"), acclimatization cannot fully compensate, and the body slowly deteriorates. Climbers in these altitudes rely on bottled oxygen or must descend quickly. The physiology here is extreme: the ventilatory drive is maximal, and yet oxygen delivery is barely adequate. The heart rate is elevated even at rest, and cardiac output may be maintained at or above sea-level values despite much lower O_2 content. The pulmonary artery pressures can be very high – many Everest climbers have been observed to have signs of pulmonary hypertension and even RV dilation. In fact, a condition known as "subacute mountain sickness" or Monge's disease can occur in long-term high altitude residents, characterized by polycythemia and pulmonary hypertension leading to cor pulmonale (right heart failure). This has been termed "high-altitude heart failure" in some reports.
In an extremely high altitude environment like the upper Himalaya, even basic tasks are exhausting. The body's compensation reaches their ceiling. An oft-cited study is "Operation Everest II," where volunteers in a chamber were taken to a simulated Everest summit over weeks. Even after full acclimatization, at the extreme altitude, their arterial PaO_2 was ~30 mmHg and SaO_2 ~70%, with resting VO_2 max drastically reduced. Despite these numbers, humans can survive – a testament to how our tissues can function at low oxygen tensions when gradually adapted. Clinically, though, if a patient with heart or lung disease were suddenly placed at 8000 m without oxygen, it would be rapidly fatal. Thus, understanding the gradient from moderate to extreme altitude helps inform how much reserve a given patient need. For instance, someone with severe COPD might struggle at 2500 m (where a healthy person's saturation is ~90%), akin to a healthy person at perhaps 5000 m. This comparison can help guide risk assessment.

Tropical vs. Temperate Environments

While not an altitude difference per se, climate (heat and humidity) can influence respiratory physiology and comfort. In tropical lowlands (hot and humid, but at or near sea level), the O_2 availability is the same as any sea-level location, but high humidity means the air is already laden with water vapor. When air is fully humidified at body temperature in the airways, it contains 47 mmHg vapor pressure of water, regardless of the starting humidity. Thus, the alveolar gas equation still uses 47 mmHg H_2O in humidified air. However, the perception of breathing humid, hot air can be that it is "heavier" or more suffocating. Humid air limits evaporative cooling from the respiratory tract, so one's body relies more on sweating (which is also hampered if humidity is high). High ambient heat can cause thermal hyperpnea, an increased respiratory rate as a cooling mechanism. Humans do some thermal tachypnea when severely overheated, though our primary cooling is via sweat. In extreme dry heat (like a desert at 45°C), we may breathe rapidly and shallowly to dissipate heat (this is a less efficient mechanism in humans but does occur at the upper limits of heat stress). In humid heat, the challenge is that sweat does not evaporate well, and the body may resort to increasing cardiac output and cutaneous blood flow, while ventilation may rise slightly due to metabolic acidosis from dehydration or simply from exertion. High humidity can also subtly reduce the fraction of O_2 in each liter of air (since water vapor displaces other gases); hot air can hold more water, so at 37°C and 100% humidity, ambient air has slightly less O_2 available per breath than at cooler temps. Asthma can also be triggered by hot humid conditions, especially if there are environmental pollutants or mold. Some patients experience bronchospasm in very humid weather (possibly due to inhaling mold spores or airway cooling when transitioning from hot outdoors to air-conditioned indoors, etc.). In contrast, a temperate climate (mild temperature and humidity) is generally most comfortable for breathing.
In tropical environments, air pollution (biomass smoke, etc.) can be a confounder. Many tropical cities have significant pollution that impacts respiratory health more than the climate itself. But focusing strictly on the climate: heat causes vasodilation and sometimes hyperventilation; humidity can give the subjective sense of breathlessness. Clinically, patients with asthma or COPD are advised to stay hydrated and cool in hot weather, avoid outdoor activity at peak heat, and use air conditioning (with caution, as overly cold AC can also irritate airways). Notably, moving from a temperate to a tropical climate at the same altitude does not require any physiological acclimatization in terms of oxygen, it's more about thermal adaptation. On the other hand, moving from a temperate sea level to a temperate high altitude definitely requires acclimatization for hypoxia.

Heart-Lung Interactions at Varying Altitudes

Altitude not only affects the lungs' ability to oxygenate, but also the dynamic interplay between the heart and lungs. Several key aspects are impacted as one ascends. One of the consistent findings at altitude is a reduction in plasma volume. Within 24–48 hours of ascent, altitude diuresis sets in as the kidneys excrete bicarbonate and excess fluid to compensate respiratory alkalosis. This diuresis can reduce plasma volume by 10–25%, effectively decreasing circulating volume and LV preload. As a result, stroke volume tends to drop at altitude. Studies have shown that after a few days at high altitude, resting stroke volume is lower than at sea level, even though heart rate is higher; thus, cardiac output may return to near baseline or slightly lower than baseline. The lower preload (from reduced volume) is a major contributor to this stroke volume reduction. The body partially compensates with tachycardia to maintain cardiac output. In practical terms, altitude can "dry out" individuals. For the heart, less preload means lower end-diastolic volumes. Echocardiography of newcomers to altitude confirms smaller LV end-diastolic dimensions compared to sea level. Interestingly, this also makes the LV appear more spherical (less distended) in some studies.

Besides volume loss, the mechanics of breathing at altitude can affect the preload. With hyperventilation, one might generate more negative intrathoracic pressure swings, potentially augmenting venous return on inspiration. However, because altitude often involves exercise (hiking) or exertion, dynamic factors like muscle pumps and sympathetic venoconstriction come into play, generally supporting venous return unless dehydration is severe. Orthostatic tolerance can decrease at altitude: people may feel dizzy standing quickly, likely because of reduced volume and perhaps altered autonomic responses. Clinically, if someone is volume depleted at altitude, excessive use of diuretics (in a patient with heart failure, for example) could compound preload reduction and cause hypotension or decreased cardiac output. Thus, altitude necessitates a fine balance in volume management for patients between volume-overloaded (which could promote edema in lungs or periphery) and avoiding over-diuresis given they already lose fluid naturally.

When it comes to the afterload, altitude has divergent effects on the two sides of the heart. For the right ventricle, altitude is an afterload increasing condition: hypoxic pulmonary vasoconstriction causes the pulmonary artery pressure to rise, so the RV must pump against higher resistance. In acute high altitude exposure, mean pulmonary artery pressure can increase by 30–50%. For example, one study noted that pulmonary artery systolic pressure went from ~20 mmHg at sea level to ~30–35 mmHg in healthy individuals at 3450 m (within a couple days). This represents a significant increase in RV afterload. If the

altitude exposure is prolonged, some people have even higher PAP, especially if they develop HAPE. The RV, if healthy, can accommodate moderate increases in afterload by increasing contractility (enhanced by sympathetic stimulation). However, if an individual has any underlying pulmonary hypertension or RV dysfunction, altitude can exacerbate it. Clinically, there have been cases of decompensated right heart failure triggered by altitude exposure in people with underlying pulmonary vascular disease or obesity hypoventilation. Even in healthy high altitude residents, chronic hypoxic pulmonary hypertension can lead to cor pulmonale (this is seen in long-time dwellers of > 4000 m who develop chronic mountain sickness).

Considering the left ventricle (systemic afterload), acutely, systemic blood pressure tends to rise at altitude due to sympathetic activation, both at rest and with exercise. An increase in systemic vascular resistance has been observed on initial ascent (likely a stress response and perhaps a direct effect of hypoxia on certain vascular beds). Thus, one could say LV afterload acutely rises (higher blood pressure). Over time, however, acclimatization may normalize or even lower systemic vascular resistance as the body adjusts. Also, the reduced blood volume at altitude can lower cardiac filling and output, which may lead to slightly lower systemic pressures after a few days despite the ongoing sympathetic tone. Thus the net effect on LV afterload is variable: initially increased (higher catecholamines and BP) but possibly normalizing or even slightly reduced with longer stay if cardiac output falls. There is also an effect of altitude on blood viscosity: rising hematocrit at altitude increases blood viscosity, which could raise afterload on both sides of the heart (more resistance in systemic and pulmonary circuits). In chronic high-altitude residents with polycythemia (Hct > 60%), the thick blood can increase the work of the heart to pump (comparable it to a form of hyper viscosity syndrome). Phlebotomy can relieve symptoms in chronic mountain sickness precisely by reducing this viscosity load.

Altitude also triggers robust autonomic changes. Hypoxia stimulates the sympathetic nervous system via chemoreceptor reflexes and possibly direct adrenal release of catecholamines. Norepinephrine levels in the blood rise significantly in the first few days at high altitude, reflecting increased sympathetic outflow. This results in tachycardia, increased cardiac contractility, and systemic vasoconstriction in some beds. Heart rate at rest goes up (often by 10–20 bpm), and heart rate for a given exercise workload is higher than at sea level (because stroke volume is lower and sympathetic tone higher). The baroreflex may also reset to a higher operating pressure. Some individuals experience palpitations or even benign arrhythmias (like premature beats) upon ascent, likely from the combination of hypoxia and catecholamines.

From a hemodynamic standpoint, the sympathetic driven increase in contractility helps maintain blood pressure when volume is down. However, it also raises myocardial oxygen demand. At 3000–4000 m, the increase in heart rate and blood pressure can raise the double product (HR × SBP) by 15–25%, increasing cardiac work. In a patient with coronary disease, this could precipitate angina if the coronary flow cannot meet the demand. There's a documented phenomenon that altitude exposure (especially if rapid) can be associated with ST changes or demand ischemia in susceptible individuals. Thus, adrenergic effects at high altitude are a double edged sword: necessary for maintaining perfusion, but potentially risky for those with cardiovascular disease. Interestingly, beta-blockers blunt the HR and BP response, which might protect the heart but at the cost of limiting performance and potentially causing more hypoxemia because a beta-blocked individual can not increase cardiac output as much. Some studies at moderate altitude showed nonselective beta-blockers reduce the BP rise but also slightly worsen oxygenation and exercise tolerance, whereas selective beta-1 blockers had a lesser effect on oxygenation. This suggests careful choice of medications for patients going to high altitude.

Clinical Implications for Cardiopulmonary Conditions

Altitude exposure can unmask latent cardiopulmonary limitations or exacerbate existing diseases. Here, we consider several common conditions and discuss the challenges high altitude presents and clinical strategies to mitigate risk. The overarching theme is that any condition involving oxygen delivery or pulmonary pressure is stressed by hypoxia and low pressure at altitude. Recognizing this, various guidelines provide recommendations for patients traveling to altitude.

Heart Failure (HF)

For patients with heart failure (whether HFrEF or HFpEF), altitude can pose significant challenges. Even a well compensated HF patient has reduced cardiac reserve, and altitude demands (tachycardia, increased BP, hypoxia) can precipitate decompensation. One key issue is oxygenation: many HF patients have chronically lower oxygen delivery due to reduced cardiac output; adding environmental hypoxemia can tip them into tissue hypoxia. Hypoxia also causes systemic vasoconstriction in some vascular beds and pulmonary vasoconstriction, which may worsen pulmonary edema risk in those with left HF. In fact, hypoxemia and elevated pulmonary pressures could exacerbate pulmonary congestion in a HF patient, potentially precipitating high altitude pulmonary edema at a lower threshold than a healthy person. Additionally, altitude diuresis can affect HF management, on one hand, the fluid loss might benefit a patient prone to volume overload; on the other, dehydration could reduce preload too much or lead to hypotension (especially if the patient is on diuretics).

Volume management is critical. HF patients are often on diuretics, and traveling to altitude may require dose adjustments. Volume depletion is a major concern for HF travelers. Patients should be euvolemic before ascent, but not excessively dry. They need to maintain fluid intake to counteract insensible losses from high altitude (increased breathing, dry air) while avoiding salt overload. Clinicians may advise a moderate reduction in diuretic dose during ascent days and close monitoring of weight or edema. Another factor is heart rate and arrhythmia. Many HF patients are on beta-blockers. At altitude, a blunted heart rate response (from beta-blockade) could limit their ability to increase cardiac output in the face of hypoxia, possibly worsening fatigue. On the flip side, stopping a beta-blocker could expose them to arrhythmias or ischemia from surging sympathetic tone. A balanced approach is needed, often continuing beta-blockers but monitoring symptoms. If a HF patient is very symptomatic at altitude, supplemental oxygen can reduce sympathetic drive and pulmonary pressures, helping both RV and LV.

Chronic Obstructive Pulmonary Disease (COPD) and Other Obstructive Diseases

Patients with COPD, especially moderate to severe disease, are among those most affected by altitude hypoxia. By definition, many have gas exchange impairment at sea level (low PaO_2 or SpO_2). At high altitude, worsening hypoxemia is a primary concern. Even a mild COPD patient with resting PaO_2 ~70 mmHg at sea level can drop to PaO_2 <55 mmHg at 2500–3000 m. Thus, significant desaturation is expected. Many COPD patients will require supplemental oxygen when traveling to altitude, even if they don't use it at sea level. Current recommendations (e.g., British Thoracic Society 2022) often use cut-offs: if a patient's sea-level PaO_2 is <60–65 mmHg or SaO_2 <92% at rest, they likely need oxygen for flights or high-altitude stays. Even patients above those thresholds can desaturate with exercise at altitude. A hypoxic challenge test in a clinic can identify who will drop below 50 mmHg PaO_2 during flight; about one-third of COPD patients with sea-level PaO_2 >72 mmHg still fell below 50 mmHg during a 15% O_2 test, indicating many "borderline" patients could need oxygen.

Altitude may affect airway mechanics in COPD in complex ways. On one hand, the lower air density at altitude reduces airway resistance (flow through bronchi may improve because thin air produces less drag). In fact, an interesting finding in a small study was an increase in FEV_1/FVC and peak flow at simulated altitude, possibly from reduced air density. On the other hand, cold air (if the altitude is cold) or exercise could provoke bronchospasm, and hypoxia can cause airway inflammation over time. Pulmonary hypertension is common in advanced COPD. At altitude, these patients are at very high risk because the already hypertensive pulmonary vessels constrict further. Long-term residents with COPD at altitude have a higher incidence of cor pulmonale (right heart failure) than those at sea level. An acute ascent could trigger RV decompensation or even HAPE in a COPD patient with secondary PH. Thus, if a COPD patient has known PH or cor pulmonale, altitude should be avoided or managed with great care.

Practical management for a COPD patient planning altitude exposure includes performing a resting SpO_2 at sea level and perhaps a 6-minute walk test with oximetry. If saturation drops below ~88% with exertion at sea level, they will definitely need oxygen at altitude. If resting SpO_2 is <92%, a high altitude simulation test (breathing ~15% O_2 for 20 min) is often done; if that yields PaO_2 <55 mmHg or symptomatic desaturation, oxygen is prescribed. Educate the patient on using portable oxygen. Also, ensure they carry rescue inhalers; inhaler technique might need adjustment because at high altitude, the propellant and air density differ minimally, but dry air could affect aerosol deposition. Advise patients to avoid sedatives or alcohol, which can depress ventilation. At night, the combination of the high

altitude hypoxia and sleep can cause significant O_2 desaturation. Thus, nighttime oxygen is advisable for COPD patients at altitude, even if daytime is borderline. Studies have reported that giving nocturnal oxygen at altitude improved symptoms in COPD travelers.

Restrictive Lung Diseases

Restrictive lung diseases pose a unique challenge, primarily causing gas exchange impairment and limited ventilatory capacity. Interstitial lung disease (ILD) patients are very prone to high altitude hypoxemia. They usually have reduced diffusion capacity and exercise-induced O_2 desaturation even at sea level. At altitude, the effect can be dramatic. Essentially, all ILD patients with anything beyond very mild disease will require oxygen at altitude. ILD often also involves pulmonary hypertension in later stages; the combination of hypoxia and existing PH can precipitate acute right heart failure or high altitude pulmonary edema in ILD patients. ILD patients also have low vital capacity and high breathing rates on exertion; at altitude, they'll reach their ventilatory limit even quicker. Those with fibrosis may develop extreme dyspnea and even ventilatory failure if they overexert at altitude. For that reason, limiting activity in the first days and gradually pacing is important. Cough is another issue: altitude can cause dry air-induced cough, and ILD patients already often have dry cough, which can be bothersome. Taking an anti-tussive or using humidified oxygen can help.

In summary, any cardiopulmonary condition that impairs oxygenation or pumping efficiency will be stressed at altitude. Heart failure patients face tachycardia, fluid shifts, and higher pulmonary pressures thus careful volume and oxygen management are needed. COPD and ILD patients face marked hypoxemia; thus, supplemental oxygen and slow ascent are imperative. Table 2 provides a comparison of altitude effects and our recommendations for common cardiopulmonary diseases.

Table 2: Effects of Altitude on Common Cardiopulmonary Diseases and Management Strategies

Condition	Main altitude risks	Pre-travel assessment	Prophylaxis/equipment	At-altitude management	Red flags → descend/ER
HF	Hypoxemia, ↑ PAP → pulmonary congestion; tachycardia ↑ myocardial O_2 demand; dehydration ↓ preload	Check stability (no recent decompensation), BP/HR, weight; consider BNP, echo if borderline; 6MWT or simple exertional oximetry	Continue GDMT; consider portable O_2 if resting SpO_2 ≤92% or desats on exertion; bring home BP monitor; avoid abrupt diuretic up-titration on ascent	Pace activity; maintain euvolemia (avoid over- and under-diuresis); low threshold for O_2 (esp. at night); CPAP if co-OSA; avoid sedatives	Rest or nocturnal dyspnea despite O_2, new edema, syncope, chest pain, SpO_2 <85–88% at rest
COPD	Marked desaturation (rest/exertion), ↑ PAP/RV strain; cold/dry air bronchospasm; sleep hypoxemia	Resting and exertional oximetry; if borderline, consider hypoxic challenge (HAST) or simulate with 15% FiO_2; review inhaler technique	Supplemental O_2 plan (flows for rest, exertion, sleep); rescue and controller inhalers; spacer; consider nocturnal O_2 even if daytime borderline; vaccinations up to date	Slow ascent; avoid triggers (cold, smoke); humidify O_2 if possible; prompt bronchodilator use; consider BiPAP if hypercapnic exacerbation	SpO_2 <85–88% on prescribed O_2, severe dyspnea, confusion/CO_2 narcosis features, signs of cor pulmonale
ILD	Severe hypoxemia; diffusion limitation; frequent exertional/ nocturnal desats; risk of PH/RV failure	Rest and exertional oximetry; many will need O_2 even if not at sea level; echo if concern for PH	Continuous O_2 plan (rest/exertion/night); portable pulse ox; cough control (humidification, antitussives PRN)	Minimize exertion early; strict pacing; HFNC or CPAP/BiPAP if available in facility for acute hypoxemia	Persistent SpO_2 <88–90% despite O_2, syncope, chest pain, signs of right heart failure

BP: Blood Pressure, HR: Heart Rate, BNP: B-type Natriuretic Peptide, 6MWT: Six-Minute Walk Test, O_2: Oxygen, SpO_2: Peripheral Oxygen Saturation, GDMT: Guideline-Directed Medical Therapy, CPAP: Continuous Positive Airway Pressure, BiPAP: Bilevel Positive Airway Pressure, HFNC: High-Flow Nasal Cannula, OSA: Obstructive Sleep Apnea, CO_2: Carbon Dioxide, RV: Right Ventricle, PH: Pulmonary Hypertension, ILD: Interstitial Lung Disease, HF: Heart Failure, HfrEF: Heart Failure with Reduced Ejection Fraction, HfpEF: Heart Failure with Preserved Ejection Fraction, RTI = Respiratory Tract Infection, SABA: Short-Acting Beta Agonist, PRN: as needed.

Respiratory Support Strategies Across Altitudes

Given the physiological stresses at altitude, various respiratory support strategies can be employed to assist both healthy climbers and patients with cardiopulmonary conditions. These include supplemental oxygen, high flow nasal cannula, positive-pressure ventilation (CPAP/BiPAP), and mechanical ventilation in extreme cases. Each tool affects heart–lung physiology in specific ways, and their use must be tailored to the altitude context and the individual's needs.

Supplemental Oxygen

This is the most direct remedy for hypoxemia. Providing additional O_2 increases the fraction of inspired oxygen (FiO_2), thereby raising alveolar and arterial PO_2 even in a low barometric pressure environment. Oxygen also attenuates hypoxic pulmonary vasoconstriction by improving alveolar O_2, it causes pulmonary arteries to dilate, lowering pulmonary artery pressure. This can prevent or treat altitude related pulmonary hypertension and edema. In patients with cardiovascular disease, supplemental O_2 thus reduces RV afterload and improves exercise tolerance. Clinically, portable oxygen is recommended for patients with significant lung disease traveling above 1500–2000 m, patients with pulmonary hypertension or HF who desaturate with minimal exertion, and anyone who develops altitude illness with O_2 sat <85–90%. Altitude trekkers or skiers with lung disease are often advised to use oxygen, especially at night, as nocturnal hypoxemia can be worse. Some healthy climbers also use supplemental O_2 as they ascend above ~7000 m to maintain function and prevent severe hypoxia; for instance, Mount Everest expeditions commonly use oxygen flow 2–3 L/min via mask at extreme altitudes, which can raise arterial O_2 saturation from ~ 65% to >85%, a huge performance and safety boost.

High-Flow Nasal Cannula (HFNC)

HFNC is a support modality that delivers heated, humidified oxygen at flow rates up to 60 L/min through nasal prongs. It can provide near 100% FiO_2 and a modest PEEP due to the high flow rate, creating resistance at the nasopharynx. At high altitude, HFNC can be extremely useful for patients with acute respiratory failure or severe altitude illness. The warmed humidification also helps in the cold, dry air of altitude by preventing airway cooling and drying. HFNC's slight PEEP effect may recruit collapsed alveoli and counteract some of the atelectasis or interstitial edema seen in HAPE, thus

improving V/Q matching. It also washes out anatomic dead space, aiding CO_2 removal. All these effects collectively reduce the work of breathing.

The heart–lung interplay with HFNC is generally positive: by improving oxygenation, it reduces reflex sympathetic drive and strain on the heart; the small PEEP can lower LV afterload slightly and improve cardiac output as seen with CPAP in HF (though HFNC's PEEP is mild). One must be cautious in severely volume depleted patients, as any positive pressure can reduce preload (but HFNC's effect is quite mild compared to CPAP). HFNC is comfortable and allows the patient to eat, talk, and ambulate (with portable units), which is ideal for acclimatization or recovery.

Continuous Positive Airway Pressure (CPAP) and Bi-level Positive Airway Pressure (BiPAP)

Positive airway pressure devices are widely used for sleep apnea, as well as acute cardiogenic pulmonary edema and COPD exacerbations. At altitude, even healthy individuals can have Cheyne–Stokes respirations during sleep (periodic breathing characterized by cyclic hyperventilation and apnea). This can cause frequent arousals and poor sleep quality. CPAP can stabilize upper airways and reduce the number of apneas/hypopneas, especially for those who have underlying obstructive sleep apnea (OSA). CPAP would help in OSA; for pure central apnea (periodic breathing), a more specialized adaptive servo-ventilator might be needed, or simply acclimatization/acetazolamide could reduce it. Nonetheless, for patients with known sleep apnea, continuing CPAP at altitude is essential as it prevents oxygen desaturation and cardiac stress overnight.

BiPAP (which provides higher inspiratory pressure support and some PEEP on exhalation) is very useful for COPD exacerbations, OHS decompensation, or acute pulmonary edema at altitude. BiPAP can also treat HAPE by improving ventilation and providing PEEP to counteract fluid in alveoli, much like it does in cardiogenic pulmonary edema. Positive pressure in general recruits alveoli and improves V/Q matching, thereby raising arterial O_2. It also reduces LV afterload and transmural pressure, which can benefit patients with high-altitude-induced left heart strain or systemic hypertension (CPAP is known to lower blood pressure modestly in hypertension). Additionally, by decreasing the work of breathing, BiPAP can help break the vicious cycle of hypoxia and tachypnea. In COPD exacerbation at altitude, BiPAP will correct hypoventilation and allow CO_2 elimination even while the patient is still in the low-oxygen environment.

Mechanical Ventilation

In severe cases of respiratory failure (such as HAPE that does not respond to oxygen or CPAP, or severe pneumonia/ARDS at altitude), invasive mechanical ventilation may be necessary. Managing a ventilator at high altitude involves unique considerations. The oxygen source is typically cylinders or concentrators. While setting the desired FiO_2 is straightforward, the partial pressure of inspired oxygen (PiO_2) is lower at altitude due to reduced barometric pressure. For example, an FiO_2 of 50% at 3000 m (where barometric pressure is ~523 mmHg) provides a PiO_2 similar to that of ~30% FiO_2 at sea level. Therefore, higher FiO_2 levels (60–100%) may be needed to achieve the same arterial oxygen saturation as 40–50% FiO_2 at sea level.

Delivered tidal volumes (measured in mL) are unaffected by altitude, but transpulmonary pressure gradients and ventilator pressure readings are relative to ambient pressure. Some ventilators may require recalibration or adjustment of pressure alarms at altitude, particularly older models. Many modern ventilators include automatic altitude compensation. Lung protective ventilation principles remain unchanged and are even more crucial in high altitude induced pulmonary edema or ARDS, where the lungs are already injured. Using lower tidal volumes, adequate PEEP, and avoiding high plateau pressures is essential to minimize ventilator induced lung injury.

Portable Hyperbaric Chamber

One special intervention for altitude illness is the portable hyperbaric chamber (e.g. Gamow bag). This is essentially a fabric chamber that can be zipped around a patient and pumped to raise the internal pressure equivalent to a descent of 1000–2000 m. It is used in the field for severe AMS/HACE/HAPE when evacuation is delayed. In physiological terms, a hyperbaric bag simulates going to a lower altitude: it increases ambient pressure around the patient, thereby increasing the partial pressure of oxygen in their lungs. A patient with HAPE placed in a Gamow bag for a few hours often shows dramatic improvement in oxygenation and symptoms, buying time for actual descent. While not a hospital “respiratory support device” per se, it is a critical emergency support in remote high-altitude medicine.

Conclusion

Altitude exposes the human cardiopulmonary system to stressors similar to a natural stress test: lower oxygen pressure, changes in intrathoracic pressure, sympathetic activation, and environmental extremes. Here, we explored how fundamental respiratory physiology (gas exchange, oxyhemoglobin affinity, ventilation–perfusion matching) and heart–lung interactions are altered across altitudes. Key principles include the drop in ambient pressure leading to hypoxemia and hyperventilation, the resulting hemodynamic changes, and the remarkable acclimatization process that partially compensates over time. We discussed how these changes impact patients with heart failure, lung diseases, and other conditions – often heightening risks of decompensation – and reviewed clinical strategies to mitigate those risks.

Ultimately, the heart–lung unit is a team, and altitude challenges that team in unique ways. A healthy person's cardiovascular and respiratory systems usually adapt well. But in someone with an underlying disease, the margin for error is thin. Clinicians must be aware of altitude physiology to provide sound advice and recommendations. Altitude-related illnesses further underscore the importance of recognizing symptom patterns and intervening early.

In conclusion, altitude medicine is an intricate interplay of foundational physiology and clinical medicine. By applying principles like gas laws and heart–lung interactions, we can predict how a given person might respond to 3000 m before they ever get there. Similarly, by leveraging modern interventions and timely interventions, we can often circumvent problems or treat them effectively. As travel and living at high altitude become more common, this knowledge becomes increasingly relevant. The human body is adaptable, but not invincible: understanding its limits at altitude allows us to test those limits safely. This chapter highlights the resilience of the cardiopulmonary system and the importance of supporting it, especially when the Earth's environment demands more than usual.

Reference

1. West JB, Luks AM. West's Respiratory Physiology: The Essentials, 11e. Lippincott Williams & Wilkins, a Wolters Kluwer business; 2021.
2. Morgan TJ. The oxyhaemoglobin dissociation curve in critical illness. Crit Care Resusc 1999; 1(1):93-100.
3. Wagner PD. Operation Everest II. High Alt Med Biol 2010 Summer;11(2):111-119.
4. Cymerman A, Reeves JT, Sutton JR, et al. Operation Everest II: maximal oxygen uptake at extreme altitude. J Appl Physiol (1985) 1989; 66(5):2446-2453.
5. Patel S, Jose A, Mohiuddin SS. Physiology, Oxygen Transport And Carbon Dioxide Dissociation Curve. 2023 In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.
6. Baylis, C., & Till, C. Interpretation of arterial blood gases. Surgery (Oxford) 2009; 27(11), 470–474.
7. Gale GE, Torre-Bueno JR, Moon RE, et al. Ventilation-perfusion inequality in normal humans during exercise at sea level and simulated altitude. J Appl Physiol (1985) 1985; 58(3):978-988.
8. Luks AM, Beidleman BA, Freer L, et al. Wilderness Medical Society Clinical Practice Guidelines for the Prevention, Diagnosis, and Treatment of Acute Altitude Illness: 2024 Update. Wilderness Environ Med 2024; 35(1_suppl):2S-19S.
9. Liu HM, Chiang IJ, Kuo KN, et al. The effect of acetazolamide on sleep apnea at high altitude: a systematic review and meta-analysis. Ther Adv Respir Dis 2017; 11(1):20-29.
10. Ibrahim A, Stefani A, Cesari, et al. Effects of periodic breathing on sleep at high altitude: a randomized, placebo-controlled, crossover study using inspiratory CO2. J Physiol 2024; 602: 5549-5568.
11. Bagshaw M, Illig P. The Aircraft Cabin Environment. Travel Medicine 2019:429–436.
12. Coker RK, Armstrong A, Church AC, et al. BTS Clinical Statement on air travel for passengers with respiratory disease. Thorax 2022; 77(4):329-350.
13. Agustí A, Celli BR, Criner GJ, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Am J Respir Crit Care Med 2023; 207(7):819-837.
14. Jacobs SS, Krishnan JA, Lederer DJ, et al. Home Oxygen Therapy for Adults with Chronic Lung Disease. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020; 202(10):e121-e141.
15. Bauer M, Müller J, Schneider SR, et al. Hypoxia-altitude simulation test to predict altitude-related adverse health effects in COPD patients. ERJ Open Res 2023; 9(2):00488-2022.

16. Sevik A, Gaisl T, Forrer A, et al. High altitudes and partial pressure of arterial oxygen in patients with chronic obstructive pulmonary disease - A systematic review and meta-analysis. Pulmonology 2025; 31(1):2416860.
17. Mallet RT, Burtscher J, Richalet JP, et al. Impact of High Altitude on Cardiovascular Health: Current Perspectives. Vasc Health Risk Manag 2021; 17:317-335.
18. Parati G, Agostoni P, Basnyat B, et al. Clinical recommendations for high altitude exposure of individuals with pre-existing cardiovascular conditions: A joint statement by the European Society of Cardiology, the Council on Hypertension of the European Society of Cardiology, the European Society of Hypertension, the International Society of Mountain Medicine, the Italian Society of Hypertension and the Italian Society of Mountain Medicine. Eur Heart J 2018; 39(17):1546-1554.
19. Cornwell WK 3rd, Baggish AL, Bhatta YKD, et al.; American Heart Association Exercise, Cardiac Rehabilitation, and Secondary Prevention Committee of the Council on Clinical Cardiology; and Council on Arteriosclerosis, Thrombosis and Vascular Biology. Clinical Implications for Exercise at Altitude Among Individuals With Cardiovascular Disease: A Scientific Statement From the American Heart Association. J Am Heart Assoc 2021; 10(19):e023225.
20. Voller J, Tobin JM, Cap AP, et al. Joint Trauma System Clinical Practice Guideline (JTS CPG): Prehospital Blood Transfusion. 30 October 2020. J Spec Oper Med 2021; 21(4):11-21.